8 results
For women with a singleton fetus in breech presentation at term, this study answers the question if atosiban is more effective compared to fenoterol as a tocolyticum in external cephalic version
To compare the effectiveness of the tocolytic agents Nifedipine (a calcium channel blocking agent) versus Atosiban (an oxytocin receptor antagonist) in the improvement of neonatal outcome in women with threatened preterm labour (25-34 weeks…
To investigate the potential of atosiban as a treatment for pain caused by endometriosis.
To assess the short term and medium term weight loss after bariatric surgery compared to conservative therapy, to determine the prevalence and the effect of weight loss on obesity associated morbidity in adolescence, to measure the effect of…
The purpose of this study is to determine whether 177Lu-PSMA-617, given for 6 cycles at a dose of 7.4 Gigabecquerel (GBq) (200 Millicuries (mCi)) +/- 10%, improves the radiographic progression free survival (rPFS) or death compared to a change in…
The primary objective of this study is to compare overall survival (OS) in patients with progressive PSMA-positive mCRPC who receive 177Lu-PSMA-617 in addition to best supportive/best standard of care versus patients treated with best supportive/…
The purpose of this study is to evaluate the efficacy and safety of 177Lu-PSMA-617 in combination with Standard of Care, versus Standard of Care alone, in adult male patientswith mHSPC.In this study, the SoC is defined as a combination of Androgen…
The aim of this study is to investigate if tocolysis with atosiban in late preterm birth (30 to 34 weeks) is (cost-) effective compared with placebo in improving neonatal morbidity and mortality.